Please use this identifier to cite or link to this item: https://doi.org/10.1159/000247001
DC FieldValue
dc.titleA double-blind, placebo-controlled, randomized phase II pilot study to investigate the potential efficacy of the traditional Chinese medicine neuroaid (MLC 601) in enhancing recovery after stroke (TIERS)
dc.contributor.authorKong, K.H.
dc.contributor.authorWee, S.K.
dc.contributor.authorNg, C.Y.
dc.contributor.authorChua, K.
dc.contributor.authorChan, K.F.
dc.contributor.authorVenketasubramanian, N.
dc.contributor.authorChen, C.
dc.date.accessioned2016-11-08T09:58:27Z
dc.date.available2016-11-08T09:58:27Z
dc.date.issued2009-10
dc.identifier.citationKong, K.H., Wee, S.K., Ng, C.Y., Chua, K., Chan, K.F., Venketasubramanian, N., Chen, C. (2009-10). A double-blind, placebo-controlled, randomized phase II pilot study to investigate the potential efficacy of the traditional Chinese medicine neuroaid (MLC 601) in enhancing recovery after stroke (TIERS). Cerebrovascular Diseases 28 (5) : 514-521. ScholarBank@NUS Repository. https://doi.org/10.1159/000247001
dc.identifier.issn10159770
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/129779
dc.description.abstractBackground and Objective: Previous clinical studies have shown that Neuroaid (MLC 601) may be beneficial in post-stroke rehabilitation. Our aim was to investigate the efficacy of Neuroaid on motor recovery in ischemic stroke patients using rehabilitation endpoints in accordance with the International Conference on Harmonization/Good Clinical Practice guidelines, in order to provide predictive information for further larger trials. Methods:This is a phase II double-blind, placebo-controlled pilot study of 40 subjects admitted with a recent (less than 1 month) ischemic stroke. All subjects were given either Neuroaid or placebo, 4 capsules 3 times a day for 4 weeks. Fugl-Meyer Assessment (FMA), National Institutes of Health Stroke Scale and Functional Independence Measure scores were measured at initiation of the treatment, and at 4 and 8 weeks. Results: None of the outcomes was statistically significant between the two groups. However, FMA scores showed a positive trend for improvement with Neuroaid treatment over time. Subgroup analysis of subjects with posterior circulation infarction and severe stroke both showed a tendency for better recovery. Conclusion: Some positive trends were observed in the Neuroaid group. A larger multicenter trial focusing on severe stroke patients is needed to better evaluate the role of Neuroaid in aiding stroke recovery in rehabilitation. Copyright © 2009 S. Karger AG.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1159/000247001
dc.sourceScopus
dc.subjectClinical trial
dc.subjectFunctional recovery
dc.subjectMotor rehabilitation
dc.subjectNeuroaid
dc.subjectStroke
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.contributor.departmentPHARMACOLOGY
dc.description.doi10.1159/000247001
dc.description.sourcetitleCerebrovascular Diseases
dc.description.volume28
dc.description.issue5
dc.description.page514-521
dc.description.codenCDISE
dc.identifier.isiut000272142600013
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

26
checked on Aug 7, 2020

WEB OF SCIENCETM
Citations

26
checked on Aug 7, 2020

Page view(s)

62
checked on Jul 31, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.